Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome by Low Dose Cytosine Arabinoside

  • H. J. Weh
  • R. Zschaber
  • A. von Paleske
  • D. K. Hossfeld
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 29)


Recent reports by Baccarani and Tura [2], Moloney and Rosenthal [9], and Housset et al. [6] prompted us to treat 12 acute myeloid leukemia (AML) and 4 myelodysplastic Syndrome (MDS) patients with low dose cytosine arabinoside (Ara-C). In all patients, conventional chemotherapy was contraindicated because of previous inefficacy, advanced age, or heavy comorbidity. Ara-C was given in a dose of 10 mg/m2 s. c. every 12 h for 14–28 days. All patients received one or two courses. If bone marrow revealed more than 5% blasts 1 week after the end of therapy, another course was started. Patients who obtained a complete or partial remission received maintenance chemotherapy with low dose Ara-C (10 mg/m2 s. c. every 12 h) for 8 days every 3 or 4 weeks.


Acute Myeloid Leukemia Polycythemia Vera Cytosine Arabinoside Bone Marrow Hypoplasia Arabinosyl Cytosine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Andrey C, Beris P, Plancherel C, de Loes S, Maurice P, Chapuis B (1983) Cytosinearabinoside ä doses reduites pour le traitement des leucemies myeloides aigues. Schweiz Med Wochenschr 113: 980PubMedGoogle Scholar
  2. 2.
    Baccarani M, Tura S (1979) Differentiation of myeloid leukaemic cells: new possibilities for therapy. Br J Haematol 43: 485CrossRefGoogle Scholar
  3. 3.
    Baccarani M, Zaccaria A, Bandini G, Cavazzini G, Fanin R, Tura S (1983) Low dose arabinosyl cytosine for treatment of myelodysplastic syndromes and subacute myeloid leukemia. Leuk Res 7: 539PubMedCrossRefGoogle Scholar
  4. 4.
    Castaigne S, Daniel MT, Tilly H, Herait P, Degos L (1983) Does treatment with ARA-C in low dosage cause differentiation of leukemic cells? Blood 62: 85PubMedGoogle Scholar
  5. 5.
    Hagenbeek A, Sizoo W, Löwenberg B (1983) Treatment of acute myelocytic leukemia with low-dose cytosine-arabinoside: results of a pilot study in four patients. Leuk Res 7: 443PubMedCrossRefGoogle Scholar
  6. 6.
    Housset M, Daniel MT, Degos L (1982) Small dose of ARA-C in the treatment of acute myeloid leukemia: differentiation of myeloid leukaemia cells? Br J Haematol 51: 125PubMedCrossRefGoogle Scholar
  7. 7.
    Lotem J, Sachs J (1974) Different blocks in the differentiation of myeloid leukemic cells. Proc Natl Acad Sei USA 71: 3507CrossRefGoogle Scholar
  8. 8.
    Manoharan A (1983) Low-dose Cytarabine therapy in hypoplastic acute leukemia. N Engl J Med 309: 1652PubMedGoogle Scholar
  9. 9.
    Moloney WC, Rosenthal DS (1981) Treatment of early acute nonlymphatic leukemia with low-dose cytosine arabinoside. In: Neth R, Gallo RC, Graf T, Mannweiler K, Winkler K (eds) Modern trends in human leukemia IV. Springer, Berlin Heidelberg New York, pp 59–62Google Scholar
  10. 10.
    Mufti GJ, Oscier DG, Hamblin TJ, Bell AJ (1983) Low doses of cytarabine in the treatment of myelodysplastic Syndrome and acute myeloid leukemia. N Engl J Med 309: 1653PubMedCrossRefGoogle Scholar
  11. 11.
    Sachs L (1978) The differentiation of myeloid leukaemia cells. New possibilities for therapy. Br J Haematol 40: 509PubMedCrossRefGoogle Scholar
  12. 12.
    Solal-Celigny P, Desaint B, Herrera A, Chastang C, Amar M, Vroclans M, Brousse N, Mancilla F, Renoux M, Bernard JF, Boivin P (1984) Chronic myelomonocytic leukemia according to FAB Classification: analysis of 35 cases. Blood 53: 634Google Scholar
  13. 13.
    Wisch JS, Griffin JD, Kufe DW (1983) Response of preleukemic syndromes to continuous infusion of low-dose cytarabine. N Engl J Med 309: 1599 62Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1985

Authors and Affiliations

  • H. J. Weh
  • R. Zschaber
  • A. von Paleske
  • D. K. Hossfeld

There are no affiliations available

Personalised recommendations